168 related articles for article (PubMed ID: 33124186)
1. Transient activation of tumoral DNA damage tolerance pathway coupled with immune checkpoint blockade exerts durable tumor regression in mouse melanoma.
Zhuo M; Gorgun FM; Tyler DS; Englander EW
Pigment Cell Melanoma Res; 2021 May; 34(3):605-617. PubMed ID: 33124186
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Antitumor Response to Immune Checkpoint Blockade Exerted by Cisplatin-Induced Mutagenesis in a Murine Melanoma Model.
Gorgun FM; Widen SG; Tyler DS; Englander EW
Front Oncol; 2021; 11():701968. PubMed ID: 34295826
[TBL] [Abstract][Full Text] [Related]
3. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
Loo K; Smithy JW; Postow MA; Betof Warner A
Front Immunol; 2021; 12():810388. PubMed ID: 35087529
[TBL] [Abstract][Full Text] [Related]
4. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS
Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703
[TBL] [Abstract][Full Text] [Related]
5. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.
Yan C; Saleh N; Yang J; Nebhan CA; Vilgelm AE; Reddy EP; Roland JT; Johnson DB; Chen SC; Shattuck-Brandt RL; Ayers GD; Richmond A
Mol Cancer; 2021 Jun; 20(1):85. PubMed ID: 34092233
[TBL] [Abstract][Full Text] [Related]
6. Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors.
Reil KA; Tsuji S; Molina E; Nelson KL; McGuire KL; Giacalone MJ
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37290924
[TBL] [Abstract][Full Text] [Related]
7. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
8. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.
Zhu L; Liu J; Chen J; Zhou Q
J Hematol Oncol; 2021 Dec; 14(1):206. PubMed ID: 34930377
[TBL] [Abstract][Full Text] [Related]
9. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
[TBL] [Abstract][Full Text] [Related]
10. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
12. Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade.
Chen S; McMiller TL; Soni A; Succaria F; Sidhom JW; Cappelli LC; Casciola-Rosen LA; Morales IR; Sankaran P; Berger AE; Deutsch JS; Zhu QC; Anders RA; Hooper JE; Pardoll DM; Lipson EJ; Taube JM; Topalian SL
J Transl Med; 2024 Mar; 22(1):241. PubMed ID: 38443917
[TBL] [Abstract][Full Text] [Related]
13. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.
McGrail DJ; Pilié PG; Dai H; Lam TNA; Liang Y; Voorwerk L; Kok M; Zhang XH; Rosen JM; Heimberger AB; Peterson CB; Jonasch E; Lin SY
Sci Transl Med; 2021 Oct; 13(617):eabe6201. PubMed ID: 34705519
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma.
Malo ME; Allen KJH; Jiao R; Frank C; Rickles D; Dadachova E
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218169
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.
Gu Y; Lin X; Dong Y; Wood G; Seidah NG; Werstuck G; Major P; Bonert M; Kapoor A; Tang D
J Exp Clin Cancer Res; 2023 Jan; 42(1):2. PubMed ID: 36588164
[TBL] [Abstract][Full Text] [Related]
16. The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications.
Hargadon KM
Br J Dermatol; 2021 Dec; 185(6):1095-1104. PubMed ID: 34185875
[TBL] [Abstract][Full Text] [Related]
17. The complementarity of DDR, nucleic acids and anti-tumour immunity.
Kornepati AVR; Rogers CM; Sung P; Curiel TJ
Nature; 2023 Jul; 619(7970):475-486. PubMed ID: 37468584
[TBL] [Abstract][Full Text] [Related]
18. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
19. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma.
Bolte LA; Lee KA; Björk JR; Leeming ER; Campmans-Kuijpers MJE; de Haan JJ; Vila AV; Maltez-Thomas A; Segata N; Board R; Harries M; Lorigan P; de Vries EGE; Nathan P; Fehrmann R; Bataille V; Spector TD; Hospers GAP; Weersma RK
JAMA Oncol; 2023 May; 9(5):705-709. PubMed ID: 36795408
[TBL] [Abstract][Full Text] [Related]
20. Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade.
Saida Y; Brender JR; Yamamoto K; Mitchell JB; Krishna MC; Kishimoto S
Cancer Res; 2021 Jul; 81(13):3693-3705. PubMed ID: 33837042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
